Melanoma Clinical Trial
Official title:
Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved?
Verified date | April 2015 |
Source | University of California, Davis |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The investigators hypothesize that everting wound edges while suturing surgical sites will result in more aesthetic scars. Additionally, we also hypothesize that small to moderate wound irregularities present at 3 months will resolve by 6 months after surgery with no intervention
Status | Completed |
Enrollment | 50 |
Est. completion date | September 2014 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Over 18 years of age - Able to give informed consent themselves - Willing to return for follow up visits Exclusion Criteria: - Mentally handicapped - Unable to understand written and oral English - Incarceration - Under 18 years of age - Unwilling to return for follow up - Pregnant Women - Wounds less than 3 cm in length |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | UC Davis, Department of Dermatology | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Davis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Everted versus non-everted suturing techniques | Primary outcome measures for this study are the post operative scar width measured at 1 cm from the midline on both sides of the scar. | 3 and 6 months | No |
Primary | Mean score of sum of 2 blinded observers POSAS scores | The mean summed total of two blinded reviewers Physician Observer Scar Assessment Scale (POSAS) scores for each side of the wound. | 3 and 6 months | No |
Primary | Scar measurements (height, width, length) | Scar volume will be measured in centimeters on both sides of the wound | 3 and 6 months | No |
Primary | Scar induration | Scar induration area will be measured in centimeters for both sides of the wound | 3 and 6 months | No |
Primary | Scar erythema | Scar erythema area will be measured in centimeters for both sides of the wound | 3 and 6 months | No |
Primary | Wound contour irregularities | Wound contour irregularities will be measured in terms of volume in cubic centimeters via a length, width and height measurement | 3 and 6 months | No |
Primary | Stand cone volume | The volume of standing cones will be measured via length, width and height measurements in centimeters | 3 and 6 months | No |
Primary | Uneven edge measurement | The area of uneven edges will be measured via a length x height measurement in centimeters | 3 and 6 months | No |
Primary | Hyperpigmentation area | areas of hyperpigmentation will be measured via a length x width measurement in centimeters | 3 and 6 months | No |
Secondary | Infection | Infections occurring anytime during the study period will be recorded | up to 6 months | Yes |
Secondary | wound dehiscence | incidence of wound infection will be recorded anytime during the study period | up to 6 months | Yes |
Secondary | spitting sutures | spitting sutures will be counted for each side of the wound at 3 and 6 months | 3 and 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|